Olfr1054 Activators
Olfr1054 Activators operate through a diverse range of mechanisms, primarily revolving around the modulation of intracellular cAMP levels and the activation of protein kinase A (PKA), which are key players in the signaling pathways involving Olfr1054. Forskolin, Epinephrine, Isoproterenol, PGE2, Histamine, Dopamine, Adenosine, and Cholera Toxin all facilitate the activation of adenylate cyclase in different contexts. This activation leads to an increase in cAMP levels within cells. The elevated cAMP serves as a secondary messenger that activates PKA. PKA then phosphorylates various substrates, including those within the signaling cascade of Olfr1054, enhancing its functional activity. This pathway demonstrates how Olfr1054 activity can be indirectly augmented through the manipulation of upstream signaling components.
Additionally, the regulation of cAMP levels is further influenced by compounds that inhibit its breakdown. IBMX, Rolipram, Zardaverine, and Anagrelide function by inhibiting phosphodiesterases, the enzymes responsible for cAMP degradation. By preventing cAMP breakdown, these compounds sustain or elevate cAMP levels, further potentiating PKA activation. The continued activation of PKA leads to enhanced phosphorylation of proteins within the signaling pathways involving Olfr1054. This sustained elevation of cAMP and consequent PKA activity exemplify how Olfr1054's functional activity can be enhanced through a sustained modulation of its signaling environment. Collectively, these activators demonstrate a strategic approach to augmenting Olfr1054's activity by targeting key regulatory points in its associated signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes responsible for breaking down cAMP. By inhibiting these enzymes, IBMX increases cAMP levels in the cell, similar to Forskolin. This rise in cAMP can enhance the PKA-mediated signaling pathways, which indirectly activates Olfr1054. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), leading to increased cAMP levels in specific cell types. Elevated cAMP activates PKA, which then can phosphorylate substrates in the signaling pathway of Olfr1054, enhancing its activity. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to adrenergic receptors, leading to adenylate cyclase activation and an increase in intracellular cAMP. The rise in cAMP and subsequent activation of PKA can enhance the signaling pathway in which Olfr1054 is involved, indirectly enhancing its activity. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a β-adrenergic agonist, stimulates adenylate cyclase via β-adrenergic receptors, increasing cAMP levels. This elevation in cAMP, followed by PKA activation, can enhance the signaling cascade involving Olfr1054. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) binds to its receptors, leading to adenylate cyclase activation and increased cAMP levels. This increase in cAMP and the subsequent activation of PKA can indirectly enhance the activity of Olfr1054 by influencing the signaling pathways it's involved in. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine, through its action on H2 receptors, activates adenylate cyclase, thereby increasing intracellular cAMP levels. The elevated cAMP and the subsequent activation of PKA may enhance the signaling pathways that involve Olfr1054. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can activate adenylate cyclase through D1-like receptors, leading to increased cAMP levels. This rise in cAMP and subsequent activation of PKA may indirectly enhance the signaling pathways involving Olfr1054. | ||||||
Adenosine | 58-61-7 | sc-291838 sc-291838A sc-291838B sc-291838C sc-291838D sc-291838E sc-291838F | 1 g 5 g 100 g 250 g 1 kg 5 kg 10 kg | $34.00 $48.00 $300.00 $572.00 $1040.00 $2601.00 $4682.00 | 1 | |
Adenosine, acting through A2A receptors, can stimulate adenylate cyclase activity, increasing cAMP levels. The increase in cAMP and subsequent activation of PKA may enhance the signaling pathways in which Olfr1054 is involved. | ||||||
Zardaverine | 101975-10-4 | sc-201208 sc-201208A | 5 mg 25 mg | $88.00 $379.00 | 1 | |
Zardaverine is a selective inhibitor of phosphodiesterases 3 and 4, leading to increased cAMP levels. This elevation in cAMP and subsequent activation of PKA can indirectly activate pathways involving Olfr1054. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase 3, resulting in increased cAMP levels. The resultant elevation in cAMP and activation of PKA can enhance the signaling pathways that involve Olfr1054. | ||||||